Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Reliance Nippon Life Asset Management Ltd has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201129-06-2016
29-06-2016
Sanofi and Boehringer Ingelheim sign definitive agreements to swap businesses
Sanofi's animal health business will go to Boehringer Ingelheim while the latter's consumer healthcare business will be integrated with the former27-06-2016
Sanofi India board elects Aditya Narayan as Chairman
Mallya will cease to be a Director and Chairman of the Board of Directors of Sanofi India Ltd at the conclusion of the company's AGM," the company had said.02-06-2016
Aditya Narayan elected as Sanofi India Limiteds Chairman of the Board of Directors
Sanofi India Ltd has informed BSE regarding a Press Release dated June 02, 2016 titled "Aditya Narayan elected as Sanofi India Limiteds Chairman of the Board of Directors".02-06-2016
Outcome of Board Meeting - Changes in Board of Directors and reconstitution of Committees
Sanofi India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 02, 2016, inter alia, has transacted the following :1. Mr. Aditya Narayan, Independent Director has been elected Chairman of the Board of Directors to hold such office as long as he is an Independent Director of the Company.It will be recalled that Mr. Aditya Narayan had been elected by the shareholders of the Company at the Annual...02-06-2016
Outcome of Board Meeting
Sanofi India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 02, 2016, Mr. Aditya Narayan has been elected as the Chairman of the Board of Directors to hold such office as long as he is an Independent Director of the Company.It will be recalled that Mr. Aditya Narayan had been elected by the shareholders of the Company at the Annual General Meeting held on April 29, 2016 as an Independent Director...02-06-2016
Shantha Biotechnics begins commercial production at new unit
Sanofi Pasteur, the vaccines division of Sanofi, today said commercial production at its affiliate Shantha Biotechnics' new vaccines manufacturing facility began on May 25.The new facility, located i...31-05-2016
Sanofi to unveil challenge to Medivation's board
Medivation has argued that Sanofi's offer fails to value fairly the prospects of its recently developed prostate cancer drug XTANDI, as well as two other products currently in clinical trials; Talazoparib, for the treatment of breast cancer, and Pidilizumab, for the treatment of blood cancers.25-05-2016
Company statement on the recall of Combiflam batches
Sanofi India Ltd has submitted to BSE a copy of the Company's statement on the recall of Combiflam batches.24-05-2016
These were tough pills to swallow
Last week, Sanofi recalled four batches of well known painkiller Combiflam on the grounds that the disintegration time of those tablets was delayed. It was a Class III recall, which implies that the r...19-05-2016